The limitations of diethylenetriamine pentaacetic acid (DTPA) use in radiological mass casualty events: Challenges and future directions
DOI:
https://doi.org/10.5055/ajdm.0505Keywords:
diethylenetriamine pentaacetic acid, mass casualty management, chemical, biological, radiological, nuclear, radiation emergency, chelation therapy, internal contamination, radiation countermeasuresAbstract
This paper examines the critical challenges associated with the use of diethylenetriamine pentaacetic acid (DTPA) as a chelating agent in radiological mass casualty incidents (MCIs). While DTPA is effective in binding and removing certain radioactive isotopes from the body, its use in MCI is significantly restricted by logistical barriers that prevent timely administration to large numbers of individuals. The requirement for delivery either intravenously or by nebulizer, which is recommended only for inhalational exposure and not approved for pediatric use, necessitates specialized medical personnel and equipment, making DTPA infeasible for MCI. This paper emphasizes the urgent need for the development of alternative countermeasures that are easy to administer to large numbers of people, suitable for both adults and children, and capable of being rapidly deployed in the event of a radiological emergency.
References
World Nuclear Association: Chernobyl accident. 1986. Updated February 17, 2025. Available at https://world-nuclear.org/information-library/safety-and-security/safety-of-plants/chernobyl-accident. Accessed April 12, 2025.
World Nuclear Association: Fukushima Daiichi accident. Updated April 29, 2024. Available at https://world-nuclear.org/informationlibrary/safety-and-security/safety-of-plants/Fukushima-daiichiaccident. Accessed April 12, 2025.
Bennett B, Repacholi M, Carr Z: Health Effects of the Chernobyl Accident and Special Health Care Programmes. Geneva: World Health Organization, 2006. Available at https://iris.who.int/bitstream/handle/10665/43447/9241594179_eng.pdf?sequence=1. Accessed May 7, 2025.
Reuters: Safety at Ukraine nuclear plant deteriorates after nearby blast, IAEA says. 2024. Available at https://www.reuters.com/world/europe/russia-accuses-ukraine-bombing-road-near-zaporizhzhianuclear-power-plant-2024-08-17/. Accessed April 12, 2025.
US Department of Health and Human Services: Ca-DTPA/Zn-DTPA (diethylenetriamine pentaacetate). Radiation Emergency Medical Management (REMM). 2022. Available at https://remm.hhs.gov/dtpa.htm. Accessed May 13, 2025.
Sandal N, Mahar R, Sharma P: Optimizing Ca-DTPA/Zn-DTPA therapy for internal decorporation: Transitioning from intravenous to oral route with insights on safety and toxicity. J Radiol Prot. 2025; 45(2): 011002. DOI: 10.1088/1361-6498/adc013.
Fisher DR, Calder SE, Mays CW, et al.: Ca-DTPA toxicity in the mouse fetus. Health Phys. 1975; 29(6): 780-782. DOI: 10.1097/00004032-197512000-00008.
Planas-Bohne F, Ebel H: Dependence of DTPA toxicity on the treatment schedule. Health Phys. 1975; 29(1): 103-106. DOI: 10.1097/00004032-197507000-00013.
An DD, Kullgren B, Jarvis EE, et al.: From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents. Chem Biol Interact. 2016; 252: 23-28. DOI: 10.1016/j.cbi.2016.03.034.
Cada DJ, Levien T, Baker DE: Pentetate calcium trisodium (Ca-DTPA) and pentetate zinc trisodium (Zn-DTPA). Hosp Pharm. 2005; 40(1): 65-71. DOI: 10.1177/001857870504000110.
Rump A, Stricklin D, Lamkowski A, et al.: The incorporation of radionuclides after wounding by a “dirty bomb”: The impact of time for decorporation efficacy and a model for cases of disseminated fragmentation wounds. Adv Wound Care (New Rochelle). 2017; 6(1): 1-9. DOI: 10.1089/wound.2016.0693.
Morita T, Tsubokura M, Furutani T, et al.: Impacts of the 2011 Fukushima nuclear accident on emergency medical service times in soma district, Japan: A retrospective observational study. BMJ Open. 2016; 6(9): e013205. DOI: 10.1136/bmjopen-2016-013205.
Ochi S, Leppold C, Kato S: Impacts of the 2011 Fukushima nuclear disaster on healthcare facilities: A systematic literature review. Int J Disaster Risk Reduct. 2020; 42: 101350. DOI: 10.1016/j.ijdrr.2019.101350.
Bioblast: DTPA. Bioblast Online Database. 2024. Available at https://www.bioblast.at/index.php/DTPA. Accessed April 26, 2025.
Rump A, Ostheim P, Eder S, et al.: Preparing for a “dirty bomb” attack: The optimum mix of medical countermeasure resources. Mil Med Res. 2021; 8(1): 3. DOI: 10.1186/s40779-020-00291-3.
Bandyopadhyay S, Baticulon RE, Kadhum M, et al.: COVID-19 pandemic and shortage of healthcare workers: The need for investment in healthcare workforce. Arch Acad Emerg Med. 2020; 8(1): e63. DOI: 10.22037/aaem.v8i1.620.
Agrawal V, Priyadarshani A, Pathak DP, et al.: Enhancing oral bioavailability of Ca-DTPA by self-double emulsifying drug delivery system (SDEDDS). Drug Dev Ind Pharm. 2024; 50(1): 78-88. DOI: 10.1080/03639045.2023.2298881.
Palmer HE, Rieksts GA, Icayan EE: 1976 Hanford americium exposure incident: In vivo measurements. Health Phys. 1983; 45(4): 893-910. DOI: 10.1016/0017-9078(83)90175-7.
ScienceDirect Topics: Uranium, plutonium, and radium.
Available at https://www.sciencedirect.com/topics/medicine-anddentistry/plutonium-238. Accessed April 26, 2025.
Mamantov T: DTPA (diethylenetriaminepentaacetate). In Nelson LS, Howland MA, Lewin NA, et al. (eds.): Goldfrank’s Toxicologic Emergencies. 11th ed. New York: McGraw-Hill Education, 2019. Available at https://accessmedicine.mhmedical.com/content.aspx?bookid=2284§ionid=248385840. Accessed April 26, 2025.
Kostial K, Kargačin B, Rabar I, et al.: Simultaneous reduction of radioactive strontium, caesium and iodine retention by single treatment in rats. Sci Total Environ. 1981; 22(2): 1-10. DOI: 10.1016/0048-9697(81)90076-0.
Sueda K, Sadgrove MP, Jay M, et al.: Species-dependent effective concentration of DTPA in plasma for chelation of 241AmI. Health Phys. 2013; 105(2): 208-214.
Taylor DM, Hodgson SA, Stradling N: Treatment of human contamination with plutonium and americium: Would orally administered Ca- or Zn-DTPA be effective? Radiat Prot Dosimetry. 2007; 127(1-4): 469-471. DOI: 10.1093/rpd/ncm299.
Reddy JD, Cobb RR, Dungan NW, et al.: Preclinical toxicology, pharmacology, and efficacy of a novel orally administered diethylenetriaminepentaacetic acid (DTPA) formulation. Drug Dev Res. 2012; 73(5): 232-242. DOI: 10.1002/ddr.21018.
Taylor DM, Volf V: Oral chelation treatment of injected 241Am or 239Pu in rats. Health Phys. 1980; 38(2): 147-158. DOI: 10.1097/00004032-198002000-00003.
Zhang Y, Sadgrove MP, Sueda K, et al.: Nonaqueous gel for the transdermal delivery of a DTPA penta-ethyl ester prodrug. AAPS J. 2013; 15(2): 523-532.
Pellmar TC, Rockwell S, Dewhirst MW, et al.: Priority list of research areas for radiological nuclear threat countermeasures. Radiat Res. 2005; 163(1): 115-123.
Cilibrizzi A, Abbate V, Chen Y-L, et al.: Hydroxypyridinone journey into metal chelation. Chem Rev. 2018; 118(14): 7657-7701. DOI: 10.1021/acs.chemrev.8b00254.
Huckle JE, Sadgrove MP, Mumper RJ, et al.: Species-dependent chelation of (241)Am by DTPA di-ethyl ester. Health Phys. 2015; 108(4): 443-450. DOI: 10.1097/HP.0000000000000230.
Russell KW, Fenton SJ, Pearson EG: The role of pediatric trauma centers in disaster preparation. Curr Treat Options Peds. 2019; 5: 267-275. DOI: 10.1007/s40746-019-00163-6.
Bliss LT: Would children be adequately protected by existing intervention levels during a radionuclear emergency? Radiat Prot Dosimetry. 2010; 142(1): 40-45. DOI: 10.1093/rpd/ncq202.
Kleinerman RA: Cancer risks following diagnostic and therapeutic radiation exposure in children. Pediatr Radiol. 2006; 36(Suppl. 2): 121-125. DOI: 10.1007/s00247-006-0191-5.
World Health Organization: National stockpiles for radiological and nuclear emergencies: Policy advice. 2023. Available at https://www.who.int/publications/i/item/9789240067875. Accessed April 12, 2025.
Right T: Akorn gets $3.5M calcium order. Contract Pharma. 2006. Available at https://www.contractpharma.com/breaking-news/akorngets-3-5m-calcium-order/#:~:text=Akorn%2C%20Inc,DTPA%20by%20the%20U.S.%20Government. Accessed May 7, 2025.
Published
How to Cite
Issue
Section
License
Copyright 2007-2025, Weston Medical Publishing, LLC and American Journal of Disaster Medicine. All Rights Reserved.
